No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: March 21, 2024

The objective of the study was to assess safety and immunogenicity mRNA-1273 COVID-19 booster vaccination when co-administered with an egg-based standard dose seasonal quadrivalent influenza vaccine (QIV). This a phase 3, randomized, open-label study. Eligible adults aged ≥ 18 years were randomly assigned (1:1) receive (50 µg) QIV 2 weeks apart (Seq group) or concomitantly (Coad group). Primary objectives non-inferiority haemagglutinin inhibition (HI) anti-Spike protein antibody responses in Coad compared Seq group. 497/498 participants randomized vaccinated Seq/Coad groups, respectively. adjusted geometric mean titer/concentration ratios (95% confidence intervals) (Seq/Coad) for HI antibodies 1.02 (0.89-1.18) A/H1N1, 0.93 (0.82-1.05) A/H3N2, 1.00 (0.89-1.14] B/Victoria, 1.04 (0.93-1.17) B/Yamagata; 0.98 (0.84-1.13) antibodies, thus meeting protocol-specified criteria. most frequently reported adverse events both groups pain at injection site myalgia. similar terms overall frequency, intensity, duration events. In conclusion, co-administration immunologically non-inferior sequential administration. Safety reactogenicity profiles (clinicaltrials.gov NCT05047770).

Language: Английский

---

Estimated Effectiveness of Coadministration of the BNT162b2 BA.4/5 COVID-19 Vaccine With Influenza Vaccine

JAMA Network Open, Journal Year: 2023, Volume and Issue: 6(11), P. e2342151 - e2342151

Published: Nov. 8, 2023

No data comparing the estimated effectiveness of coadministering COVID-19 vaccines with seasonal influenza vaccine (SIV) in community setting exist.

Language: Английский

---

Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference

Clinical Microbiology and Infection, Journal Year: 2024, Volume and Issue: 30(5), P. 653 - 659

Published: Jan. 21, 2024

Language: Английский

---

Safety, reactogenicity, and immunogenicity of Ad26.COV2.S co-administered with a quadrivalent standard-dose or high-dose seasonal influenza vaccine: a non-inferiority randomised controlled trial

EClinicalMedicine, Journal Year: 2025, Volume and Issue: 79, P. 103016 - 103016

Published: Jan. 1, 2025

Vaccine co-administration can increase vaccination coverage. We assessed the safety, reactogenicity, and immunogenicity of concomitant administration Ad26.COV2.S COVID-19 vaccine with seasonal influenza vaccines. This non-inferiority, Phase 3, randomised, double-blind study enrolled 859 healthy adults was conducted between 02 November 2021 28 2022. Participants aged ≥18-64 years were randomised to receive a quadrivalent standard dose (SD) (Afluria Quadrivalent, Seqirus) concomitantly (Coad_SD) or placebo (0.9% NaCl; Control_SD) on Day 1 29. ≥65-years Coad_SD Control_SD groups, Coad_HD Control_HD groups that received HD (high-dose) (Fluzone High-Dose Sanofi Pasteur Inc) in same schedules. The primary outcomes haemagglutinin inhibition titres against four strains at 29, SARS-CoV-2 Spike-specific antibodies 29 group 57 Control-SD group, non-inferiority margin (Control-SD group/Coad_SD group) 1.5. Reactogenicity safety all participants (NCT05091307). Non-inferiority criteria for SD met (ratio 1.11, 95% CI 0.97-1.26) (A/H3N2 1.23, 1.05-1.45; B/Victoria 0.99, 0.84-1.19; B/Yamagata, 1.03, 0.88-1.21) except A/H1N1 (1.28, 1.09-1.53) which upper limit >1.5. Concomitant induced robust immune responses terms strains. Seroconversion seroprotection rates comparable Coad Control groups. Anti-Spike days after receiving similar whether administered alone. Antibody persisted least 6 months post-vaccination reactogenicity profile following consistent known profiles No concerns identified. Coadministration immunogenic well tolerated ≥65 who vaccine. Co-administration an acceptable profile, supporting these Janssen Vaccines & Prevention BV Biomedical Advanced Research Development Authority.

Language: Английский

---

Safety and Immunogenicity of Concomitant Administration and Combined Administration of Bivalent BNT162b2 COVID-19 Vaccine and Bivalent RSVpreF Respiratory Syncytial Virus Vaccine with or Without Quadrivalent Influenza Vaccine in Adults ≥ 65 Years of Age

Vaccines, Journal Year: 2025, Volume and Issue: 13(2), P. 158 - 158

Published: Feb. 5, 2025

Concomitant administration may improve vaccination rates. This analysis of a phase 1/2 randomized study included 1073 healthy ≥65-year-olds who previously received ≥3 mRNA COVID-19 vaccine doses. Participants concomitantly administered RSVpreF and bivalent BA.4/BA.5-adapted BNT162b2 (concomitant administration) with or without quadrivalent influenza (QIV), admixed combined + (combined vaccine) QIV, RSVpreF, BNT162b2, QIV. Immunogenicity objectives demonstrating the noninferiority neutralizing antibody titers elicited by concomitant compared alone, given QIV alone. Reactogenicity (≤7 days) safety ≤1 month (adverse events (AEs)) ≤6 months (serious AEs (SAEs)) after were assessed. Noninferiority for all immunogenicity comparisons was demonstrated. All groups well tolerated; no new concerns identified. mostly mild/moderate rates generally similar across groups, except injection site pain fatigue, which less frequent placebo vs. other groups. infrequent, mild/moderate, occurring at frequencies No leading to withdrawal vaccine-related SAEs reported. Favorable tolerability alongside provide support use help protect older adults from these important respiratory pathogens (NCT05886777).

Language: Английский

---

Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads to enhanced immune responses to influenza virus and reduced immune responses to SARS-CoV-2 in naive mice

Vaccine, Journal Year: 2025, Volume and Issue: 50, P. 126825 - 126825

Published: Feb. 7, 2025

Language: Английский

---

Co-Administration of BNT162b2 COVID-19 and Influenza Vaccines in Adults: A Global Systematic Review

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 381 - 381

Published: April 2, 2025

Background/Objectives: Co-administration of BNT162b2 with licensed seasonal influenza vaccines (SIVs) is recommended by health authorities. We provide a comprehensive summary the data supporting this practice in adults. Methods: This systematic review consolidates available evidence on prevalence, safety, immunogenicity, efficacy, and effectiveness co-administering SIVs. Searches were conducted for English studies adults ≥ 18 years age between January 2021 August 2024, no geographic restriction. Study quality was assessed using Cochrane RoB 2.0 Newcastle–Ottawa Scale. Results: Twenty (15 observational 5 clinical trials) included, mainly seven countries Europe North America. Eight reported twelve safety/reactogenicity, six three evaluated efficacy/effectiveness. Reported co-administration SIVs increased over time. Of persons receiving BNT162b2, proportion that co-administered from 2.7% to 34.1% 2023. Although variability outcomes observed, consistent pattern indicating negative impact immunogenicity same-day identified. Effectiveness not observed change when BNT162B2 The incidence systemic local adverse events comparable individuals separately those them co-administered. Conclusions: findings indicate both safe effective. highlights value co-administration, which could enhance vaccine uptake streamlining immunization protocols reducing visits.

Language: Английский

---

Estimating the Public Health and Economic Impact of Annual mRNA COVID-19 Vaccination for Adults Aged 50 and Older in South Korea’s Endemic Era

Vaccines, Journal Year: 2025, Volume and Issue: 13(4), P. 386 - 386

Published: April 3, 2025

Background/Objectives: COVID-19 continues to challenge public health due emerging variants. To mitigate this, the Korea Disease Control and Prevention Agency (KDCA) recommends annual vaccination, but uptake remains suboptimal. This study evaluates economic impact of mRNA vaccination for adults aged 50 older in South during 2024–2025 season, focusing on hospitalizations costs. Methods: We estimated prevented by mRNA-1273 XBB.1.5 containing vaccine calculating symptomatic infection incidence rates, hospitalization rates among unvaccinated individuals, effectiveness (VE) against hospitalization, rates. Incidence with an were derived adjusting overall based coverage VE Hospitalization costs obtained from a real-world dataset, integrating KDCA’s confirmed cases National Health Insurance claims data. Comparative analyses between BNT162b2 used published meta-analysis results. Results: Assuming remain consistent 2023–2024 is projected prevent 37,200 save USD 77.2 million healthcare season compared no vaccination. Compared BNT162b2, it expected additional 13,260 saving 27.5 million. If increased match influenza, could rise 79,800 164.2 savings Conclusion: Annual substantially reduces Increasing are essential maximize benefits.

Language: Английский

---

Assessing the determinants of influenza and COVID-19 vaccine co-administration decisions in the elderly

Human Vaccines & Immunotherapeutics, Journal Year: 2024, Volume and Issue: 20(1)

Published: May 13, 2024

This research examines the low rate of co-administration influenza and COVID-19 vaccines among seniors aged 65 older in Korea, despite recommendations from authorities academia worldwide. The study aimed to understand influence general characteristics health beliefs on vaccination choices seniors, who were categorized into four groups based their status: only, both, or neither. A total 400 participants, above, selected through proportional stratified random sampling five major Korean regions for a survey conducted between November 24th December 15th, 2023. results indicated no significant differences across these groups. However, regarding showed perceived susceptibility self-efficacy influenza-only Higher levels associated with choosing co-administration. Contrary previous studies focusing safety concerns as primary factor vaccine hesitancy, this highlights role individual health-related beliefs, particularly self-efficacy, critical influencing decision elderly Korea.

Language: Английский

---

Immunogenicity of Co-Administered Omicron BA.4/BA.5 Bivalent COVID-19 and Quadrivalent Seasonal Influenza Vaccines in Israel during the 2022–2023 Winter Season

Vaccines, Journal Year: 2023, Volume and Issue: 11(10), P. 1624 - 1624

Published: Oct. 22, 2023

Vaccination against COVID-19 and influenza provides the best defense morbidity mortality. Administering both vaccines concurrently may increase vaccination rates reduce burden on healthcare system. This study evaluated immunogenicity of workers in Israel who were co-administered with Omicron BA.4/BA.5 bivalent vaccine 2022-2023 quadrivalent vaccine. SARS-CoV-2 neutralizing antibody titers measured via microneutralization while hemagglutination inhibition. No immunogenic interference was observed by either when co-administered. Antibody variants increased significantly cohort receiving alone combination A/H1N1 strain B/Victoria that received vaccines. has important public health implications for 2023-2024 winter season, supports co-administration as a viable immunization strategy.

Language: Английский

---